Should pharma Companies avoid Mobile apps? and DigitalHealth

Its easier to say current mobile app model is broken, but at same time they still offer advantages atleast in the first few years when a drug enter the market. But the truth is these apps seldom becomes useful for the larger audience.

Pharma Mobile App Problems

Study among 1814 physicians in 25 specialties shows often pharmaceutical sales reps show medical information that physicians have seen already through other digital and non-digital channels, and most often those digital channels and content are often not even created by pharma companies

Thats because current Pharma Digital projects often run in isolation to a range of existing patient/physician outreach channels, including: e-mail marketing, rep-triggered emails, web-events (webcasts, of conferences and meetings), videos, self-guided e-detailing, remote detailing, product websites, treatment and diagnostic tools (apps), training courses (CME)

Digital to Beyond the Pill

Most pharma companies already uses a central system to manage their websites but nothing of similar nature exists for other digital channels especially the mobile apps. The early concepts of “Digital Factory” where confined to merely outsourcing resources involved in infrastructure and content development to a single IT/BPO vendor. The mobile app Factory need to become essential part of the Digital Pharma 2.0 changes.

Most of the DigitalHealth apps have failed or have seen usage metrics going down after initial hype. Most #digitalhealth apps and #startups fail after initial success because, while we cherish our health we hate being reminded about our sickness.

Read the rest of the Original article at Linkedin 

Advertisements

France to invest €670 million euros for Genomics and Personalized Medicine

Government of France Announce plans to invest €670 million euros or ($760.8 million) for Genomics and Personalized Medicine which will see it establish 12 genome sequencing centers and two national centers for genomic expertise and data analysis. The program would initially focus on cancer, diabetes and rare diseases but after 2020 would expand to include common diseases.

This investment by France follows the release on Wednesday of a report by medical experts examining the possibility of France widening access to genetic medicine within 10 years. A key objective in the report for the first 10 years of the programme is to prepare for the integration of genomic medicine into the normal course of patient care in the country, which means sequencing about 235,000 genomes per year by 2020.

Health Minister Marisol Touraine said Investment in the five year initiative will also come from industry. He also expected Companies like Google, Amazon, Apple and Facebook are interested in the growing genomic medicine sector

Several European countries have already begun to integrate genomic medicine into their health systems and there are large scale genomic initiatives in the UK, US and China. China has even recently announced a Precision Medicine Cloud

 

 

personalized medicine might be making drug development more complicated

According to a new report from the Tufts Center for the Study of Drug Development at Tufts University 12 to 50 percent of the drugs companies are developing, depending on the company, involved a personalized medicine approach.

The Tufts report is based on a survey of 25 companies, large and small, to which 16 companies responded, as well as interviews with representatives of 13 companies.

Relatively few drugs are now accompanied by such so-called companion diagnostic tests. They are most common in oncology. The breast cancer drug Herceptin, for instance, is given only to women whose tumors have an abundance of a protein called Her2.

According to the report Other key therapeutic areas in which personalized medicine is making headway include cardiovascular, central nervous system, and immunologic therapies, whereas personalized medicine development is just getting started for metabolic and respiratory therapies, as well as virology.

 

Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs

The Institute is focused on research that will accelerate IT innovation to advance personalized medicine and the delivery of safe and effective   treatments and health care services to patients around the globe. OHSI will work in tandem with academic research centers, focusing on a targeted set of research areas fundamental to the R&D and health care delivery challenges facing health sciences organizations today. Research priorities currently include: artificial intelligence and semantic technology; genomic, genetic and phenotypic data analysis; data mining to support optimization of clinical trials; and predictive algorithms and other technology to advance patient safety and provide advanced decision support at the point of care.Academic institutions interested in collaborating with OHSI in these focus areas should contact OHSI representatives at Oracle http://linkd.in/bXf98c
Oracle starts Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs. This is exiting news and I hope we get to see the participation of Open Source Drug Development Network (OSDD) and initiative by CSIR India earlier supported by Sun Microsystems
%d bloggers like this: